Research with Biological Materials & Data

Studies that involve the establishment of databases and/or biorepositories are subject to IRB review. Likewise, studies that plan to use data or samples previously collected for research or clinical purposes may also be subject to IRB review. The information on this page will assist investigators in determining whether their project requires IRB review, identify issues to consider during protocol development and clarify IRB review requirements specific to research proposing to use, store and/or maintain data or biological materials for research purposes.



Submission Process for Secondary Use - Human Subjects

1.  Create a new project application in iRIS.

2.  Create the protocol by using the Data/Specimen Collection and Use template:

          i.  Research is limited to the use of previously collected data and/or
              specimens.
         ii.  Research establishing a bank or repository using previously
              collected data and/or specimens.

3.  Complete all supplemental forms identified in the New Protocol Application checklist. 

4.  Submit all materials via iRIS.


Submission Process for Secondary Use - Not Human Subject Research

1.  Create a new project application request in iRIS.

2.  Supplemental Documents - If you do not have a research proposal (e.g. grant) or other
     supporting documents (e.g. OncDRS submission), you may create a brief protocol
     describing the research activity using the Data/Specimen Collection and Use
     protocol template.

3.  Complete all supplemental forms identified in the New Protocol Application checklist. 

4. Submit all materials through iRIS.


Additional Resources

The resources below provide additional guidance on research with biological materials and data.

1.  The NIH FAQ page answers a variety of common questions.

2.  OHRP Guidance on Biological Materials and Data

3.  NCCN Points to Consider on the Best Practices for Biorepositories, Registries and Databases.

4.  OHRP Issues to Consider in the Research Use of Stored Data or Tissues

5. NIH Best Practices for Biospecimen Resources

6. OncDRS requests


OHRS Verification For Data or Material Transfer

In order to transfer data or specimens to another institution or organization, a Material Transfer Agreement (MTA) or Data Usage Agreement (DUA) may be required. To determine if one of these agreements is required, contact your institutions technology transfer office; contact information can be found below under "Biospecimen Research Contact Information."

If it is determined that an agreement is required, the investigator must submit a Verification Request in iRIS; OHRS will work with the investigator(s) determine whether or not the request is appropriate. 


Biospecimen Research Contact Information

For Questions Regarding: Please Contact: Contact Information:


IRB and Regulatory Requirements
(including the Privacy Board)

  • Casey Rich, CIP, or
  • The Human Research Coordinator (HRC) for the trial

Casey_Rich@dfci.harvard.edu

http://www.dfhcc.harvard.edu/research/clinical-research-support/office-for-human-research-studies/ohrs-contact-list/


Clinical Trials Agreements for Clinical Trials

(e.g., Materials Transfer Agreements, Lab Services Agreements, Data Transfer Agreements, Collaboration Agreements)
  • BCH: Fernando Valles, Director Boston Children's Hospital Clinical Trials Office
  • BIDMC: Technology Ventures Office
  • DFCI: Mary Melloni, Clinical Trials Agreements Office, or the Clinical Trial Agreement Associate for the trial
  • Partners (MGH and BWH): Maureen Lawton, Director of Partners Clinical Trial Office

 

 

 Fernando.valles@childrens.harvard.edu

 

 tvo@bidmc.harvard.edu

 

Mary_Melloni@dfci.harvard.edu

 

mlawton@partners.org

 


Transfer and Usage Agreements Non-Clinical Trials

(e.g., Materials Transfer Agreements, Lab Services Agreements, Data Transfer Agreements, Collaboration Agreements, Sponsored Research)

  • BCH: Boston Children's Hospital Technology and Innovation Development Department
  • BIDMC:  Technology Ventures Office
  • DFCI: Nicole Kousmanidis, Belfer Office for Dana-Farber Innovations (BODFI), or a member of your Cluster in BODFI
  • Partners (MGH and BWH): Partners Innovation

 

http://tido.childrenshospital.org/

 

http://tvo.bidmc.org/

 

https://www.dana-farber.org/research/innovations_

https://innovation.partners.org/


Grants and Contracts
  • BCH: Boston Childen's Clinical Trials Business Office
  • BIDMC: Jennifer Sabbagh, Grants Contracts Office
  • DFCI: Tina DaSilva, Director, DFCI Grants and Contracts
  • Partners (MGH and BWH):  Partners Innovations

 

CTBO@Childrens.harvard.edu 

jsabbagh@bidmc.harvard.edu

 

Tina_DaSilva@dfci.harvard.edu

 https://innovation.partners.org/